HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Electrolyte Imbalance · Calcium Supplement Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Electrolyte Imbalance · Calcium Supplement Therapeutic Area Assessment

4 signals · 0 insights · 20 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 23, 2026

Confidence

Low Confidence · 58%

Evidence

24 items

Sources

2

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Electrolyte Imbalance · Calcium Supplement integrates 4 signals, 0 executive insights, and 20 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJul 21, 2026

    FDA Grants Approval for Lupin's Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride

    The FDA has approved ANDA216095 for a combination product containing sodium sulfate, magnesium sulfate, and potassium chloride.

    View detail
  2. signalJul 19, 2026

    Feasibility Study on IRE System for Adenotonsillar Hypertrophy in Children

    A multi-center feasibility study is underway to assess the safety and efficacy of the IRE System for treating adenotonsillar hypertrophy in children.

    View detail
  3. signalJul 16, 2026

    FDA Approves Original Application for Magnesium Sulfate by Square Pharms PLC

    The FDA has approved the original application ANDA217461 for Magnesium Sulfate submitted by Square Pharms PLC.

    View detail
  4. signalJul 12, 2026

    FDA Accepts ANDA for Calcium Gluconate by Caplin

    The FDA has accepted the Abbreviated New Drug Application (ANDA) for Calcium Gluconate submitted by Caplin.

    View detail
  5. regulatoryJul 21, 2026

    FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)

    Application NDA209552. Sponsor: EUGIA PHARMA SPECLTS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.

    View detail
  6. regulatoryJul 21, 2026

    FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)

    Application NDA022434. Sponsor: CIPLA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.

    View detail
  7. regulatoryJul 21, 2026

    FDA AP — SODIUM THIOSULFATE (SUPPL)

    Application NDA203923. Sponsor: HOPE PHARMS. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: SODIUM THIOSULFATE.

    View detail
  8. regulatoryJul 21, 2026

    FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)

    Application NDA206769. Sponsor: TEVA PHARMS USA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Insight synthesis pending additional signal clustering in this therapeutic area. 20 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 1 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)

    66%

    Application NDA209552. Sponsor: EUGIA PHARMA SPECLTS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.

    Source: FDA

    View evidence

  • FDA AP — ARGATROBAN IN SODIUM CHLORIDE (SUPPL)

    66%

    Application NDA022434. Sponsor: CIPLA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.

    Source: FDA

    View evidence

  • FDA AP — SODIUM THIOSULFATE (SUPPL)

    66%

    Application NDA203923. Sponsor: HOPE PHARMS. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: SODIUM THIOSULFATE.

    Source: FDA

    View evidence

  • FDA AP — ARGATROBAN IN 0.9% SODIUM CHLORIDE (SUPPL)

    66%

    Application NDA206769. Sponsor: TEVA PHARMS USA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.

    Source: FDA

    View evidence

  • FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

    84%

    Why this matters: illustrates how regulators handled a comparable approval decision relevant to Lupin; the same agency is already in play for this signal, so precedent weight is higher.

    Source: FDA

    View evidence

  • [ANZEN]PMDA Alert for Proper Use of Drugs: Serious hypocarnitinemia and hypoglycaemia in children treated with antibacterials with a pivoxil group (follow-up report) posted

    83%

    PMDA regulatory document relevant to this signal.

    Source: PMDA

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Grants Approval for Lupin's Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride

    Regulatory Approval

  • Feasibility Study on IRE System for Adenotonsillar Hypertrophy in Children

    Trial Update

  • FDA Approves Original Application for Magnesium Sulfate by Square Pharms PLC

    Regulatory Approval

  • FDA Accepts ANDA for Calcium Gluconate by Caplin

    Regulatory Approval

Companies

  • Lupin

    13 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.